18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- 2 year progression-free survival
研究概览
简要总结
The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of diffuse large B-cell lymphoma can predict disease progression
详细描述
In this study investigators develop a prognostic model based on 18F-FDG PET/CT and test its ability for prognostic value in patients with DLBCL. PET/CT scans evaluation using the liver SUVmax as reference. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold (1.6 fold of liver SUVmax) or new 18F-FDG avid lesions. 18F-FDG PET/CT-based prognostic model includes PET/CT image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in DLBCL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •newly diagnosed DLBCL;
- •treated using an anthracycline-containing regimen with or without rituximab;
- •minimal follow-up at 6 months after the completion of first-line treatment;
- •complete medical history and clinicopathological data
排除标准
- •secondary malignant disease;
- •serious infection or inflammation (e.g., HIV);
- •primary central nervous system lymphoma;
- •hepatic or renal dysfunction.
结局指标
主要结局
2 year progression-free survival
时间窗: up to 2 years after initial diagnosis
次要结局
未报告次要终点
研究者
Xuejuan Wang,MD
Department of Nuclear Medicine
Peking University Cancer Hospital & Institute